Abstract:Local control rates after SCRT (50 Gy) are very poor in advanced esophageal cancer. Most local failures (LF) occur in the GTV. HFRT allows for delivering a higher total dose without increasing late toxicity. We hypothesized that the use of HFRT boost to the GTV after SCRT using modern image-guided intensity-modulated radiation therapy (IG-IMRT) could potentially intensify local therapy and subsequently improve outcomes. The primary objective of this phase I trial was to define the maximum tolerated dose (MTD) of the HFRT boost with concurrent weekly C/P following SCRT. Patients (pts) who were inoperable or medically unresectable and metastatic with life expectancy ≥ 4 months were eligible. The lower thoracic esophageal cancer involving the stomach was ineligible. Pts were treated with weekly P at 45 mg/m2 and C area under the curve 1.5 with concurrent 50 Gy of IG-IMRT given in 25 fractions for 5 weeks, immediately followed by an image-guided intensity-modulated HFRT boost to the GTV concurrent with the same chemotherapy regimen. The boost doses were escalated ranging from 7.2 to 43.2 Gy in increments of 7.2 Gy delivered in 6 twice daily fractions of 1.2 Gy using a modified Fibonacci design. A minimum of 6 weeks follow-up was required after completion of radiation treatment before proceeding to the next dose. Dose limiting toxicity (DLT) was defined as grade ≥ 4 esophagitis or any other grade ≥ 3 non-hematological toxicity (except nausea and vomiting) or grade ≥ 4 hematological toxicity lasting more than 7 days, which are possibly, probably or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. The MTD was defined as the highest radiation dose at which ≤ 1 pts experienced DLT. Once the MTD was determined, this cohort was expanded to further define the safety profile. Adjuvant chemotherapy was optional. Thirty-four pts were enrolled and 31 were assessable (median age, 62 years; 73% male; 97% T3-4 disease, 65% N1-2 disease; 9% M1 disease; 97% squamous cell carcinoma; 90% PS 0-1).SCRT was well tolerated. The incidence of DLT was 0/3, 0/3, 0/3, 1/6 (grade 4 esophagitis), 0/3, 2/3 (grade 5 esophageal fistula and grade 3 pneumotitis each) at 7.2, 14.4, 21.6, 28.8, 36, and 43.2 Gy, respectively, thus defining the MTD at 36 Gy. In the expansion cohort of 10 pts at the MTD, no DLTs were encountered. The most common acute grade 3 or greater toxicities throughout the entire study period were esophagitis (26%) and neutropenia (19%). Late toxicity included grade 2 esophageal stricture (n = 4). The overall response rate was 84% (95% CI, 42% to 93%; 100% at a dose of ≥ the MTD). With a median follow up of 5 months (range 1 to 12 months), no LF was observed, and distant failure occurred in 3 pts. The MTD of a HFRT boost was determined to be 36 Gy using IG-IMRT with concurrent P and C following 50 Gy of SCRT, resulting in the total combined tumor dose of 86 Gy. Preliminary efficacy data are encouraging. A Phase II study to further evaluate this regimen is underway.

The Radiotherapy of Locally Advanced Esophageal Cancer of Inoperable Forms with Escalated Dose of 66-70 Gy

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Phase I Study of Dose-Escalated Intensity-Modulated Hyperfractionated Radiation Therapy (HFRT) Boost with Concurrent Paclitaxel (P) and Carboplatin (C) to Gross Tumor Volume (GTV) Following Standard-Dose Chemoradiotherapy (SCRT) for Advanced Esophageal Ca

Phase 2 Study of Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy

Three-dimensional conformal radiation therapy for squamous cell carcinoma of the esophagus: a prospective phase I/II study.

Impact of Radiotherapy, Chemotherapy and Surgery in Multimodal Treatment of Locally Advanced Esophageal Cancer

Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma

Radiotherapy target volumes in esophageal cancer: The twisting kaleidoscope

Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity

Clinical Study of Late-Course Three-Dimensional Conformal Radiotherapy for Esophageal Carcinoma

Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma

Long-Term Outcomes of Three-Dimensional Conformal Radiation Therapy Without Chemotherapy for Esophageal Squamous Cell Carcinoma: A Final Report of a Phase 2 Study

Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03)

Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation

Radiotherapy for patients with esophageal cancer aged 80 years or older: A 16-year experience

Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients

Impact of radical dose escalation by endoluminal brachytherapy and induction chemotherapy in the definitive treatment of locally advanced esophageal cancer - A retrospective study